triple hormone receptor agonist retatrutide First phase 3 data, a Triumph of Science! retatrutide - Diabetes In Control
Description
GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity
A: Its FDA-approved for type 2 diabetes
Common Side Effects Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and fatigue
And the ATTAIN-MAINTAIN trial in Nature Medicine showed patients can switch from injection to a daily pill and keep 75-80% of their weight loss
Diana Isaacs (Cleveland Clinic), Coach Beverly (30+ years of experience), and Christine Craig (nutrition whiz)
The specific dose depends on your baseline B12 level, dietary sources, and how long you plan to continue semaglutide therapy
